The osteo-metabolic phenotype of COVID-19: an update.
COVID-19
Hypocalcemia
Long-COVID
Osteo-metabolic phenotype
Vertebral fractures
Vitamin D
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
30
05
2022
accepted:
03
07
2022
pubmed:
21
7
2022
medline:
25
10
2022
entrez:
20
7
2022
Statut:
ppublish
Résumé
In the multifaceted COVID-19 clinical scenario characterized by a multi-system disorder with negative implications not only on respiratory function but also on cardiac, hematological, neurological and endocrine-metabolic systems, a distinctive osteo-metabolic phenotype with an independent influence on disease severity and recovery of patients affected was early reported. To summarize and update the main evidences regarding the distinct components of this phenotype in acute and Long COVID-19, reinforcing its clinical relevance and discussing the main pathophysiological and clinical-therapeutic implications of the most recent reported findings. This emerging phenotype is characterized by a widespread acute hypocalcemia and hypovitaminosis D with an impaired compensatory parathyroid hormone response, and a high prevalence of skeletal complications such as vertebral fractures. The clinical relevance of this osteo-metabolic phenotype on acute COVID-19 is well characterized, and novel seminal evidences are progressively highlighting its importance also in predicting patient's long-term outcomes and Long COVID-19 occurrence. These findings reinforced the central role of a multidisciplinary team, including endocrinologists, in evaluating these patients for a proactive search of each aspect of the osteo-metabolic phenotype components since they may represent suitable therapeutic targets to prevent SARS-CoV-2 infection, poor COVID-19 outcomes, Long COVID-19 occurrence and even possibly better responses to COVID-19 vaccination.
Identifiants
pubmed: 35857271
doi: 10.1007/s12020-022-03135-3
pii: 10.1007/s12020-022-03135-3
pmc: PMC9297261
doi:
Substances chimiques
COVID-19 Vaccines
0
Parathyroid Hormone
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
247-254Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
A. Gupta, M.V. Madhavan, K. Sehgal et al. Extrapulmonary manifestations of COVID-19. Nat. Med. 26(7), 1017–1032 (2020). https://doi.org/10.1038/s41591-020-0968-3
doi: 10.1038/s41591-020-0968-3
pubmed: 32651579
M. Puig-Domingo, M. Marazuela, A. Giustina, COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Endocrine 68(1), 2–5 (2020). https://doi.org/10.1007/s12020-020-02294-5
doi: 10.1007/s12020-020-02294-5
pubmed: 32279224
pmcid: 7150529
M. Puig-Domingo, M. Marazuela, B.O. Yildiz, A. Giustina, COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology. Endocrine 72(2), 301–316 (2021). https://doi.org/10.1007/s12020-021-02734-w
doi: 10.1007/s12020-021-02734-w
pubmed: 33963516
pmcid: 8105151
M. Marazuela, A. Giustina, M. Puig-Domingo, Endocrine and metabolic aspects of the COVID-19 pandemic [published correction appears in Rev Endocr Metab Disord. 2021 Mar;22(1):145]. Rev. Endocr. Metab. Disord. 21(4), 495–507 (2020). https://doi.org/10.1007/s11154-020-09569-2
doi: 10.1007/s11154-020-09569-2
pubmed: 32643004
pmcid: 7343578
A. Giustina, J.P. Bilezikian, Revisiting the endocrine and metabolic manifestations of COVID-19 two years into the pandemic. Rev. Endocr. Metab. Disord. 23(2), 133–136 (2022). https://doi.org/10.1007/s11154-022-09716-x
doi: 10.1007/s11154-022-09716-x
pubmed: 35182326
pmcid: 8857394
Y. Zhou, J. Chi, W. Lv, Y. Wang, Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab. Res. Rev. 37(2), e3377 (2021). https://doi.org/10.1002/dmrr.3377
doi: 10.1002/dmrr.3377
pubmed: 32588943
L. Scappaticcio, F. Pitoia, K. Esposito, A. Piccardo, P. Trimboli, Impact of COVID-19 on the thyroid gland: an update. Rev. Endocr. Metab. Disord. 22(4), 803–815 (2021). https://doi.org/10.1007/s11154-020-09615-z
doi: 10.1007/s11154-020-09615-z
pubmed: 33241508
S. Frara, A. Allora, L. Castellino, L. di Filippo, P. Loli, A. Giustina, COVID-19 and the pituitary. Pituitary 24(3), 465–481 (2021). https://doi.org/10.1007/s11102-021-01148-1
doi: 10.1007/s11102-021-01148-1
pubmed: 33939057
pmcid: 8089131
S. Frara, P. Loli, A. Allora et al. COVID-19 and hypopituitarism. Rev. Endocr. Metab. Disord. 23(2), 215–231 (2022). https://doi.org/10.1007/s11154-021-09672-y
doi: 10.1007/s11154-021-09672-y
pubmed: 34387832
L. di Filippo, S. Frara, A. Giustina, The emerging osteo-metabolic phenotype of COVID-19: clinical and pathophysiological aspects. Nat. Rev. Endocrinol. 17(8), 445–446 (2021). https://doi.org/10.1038/s41574-021-00516-y
doi: 10.1038/s41574-021-00516-y
pubmed: 34079100
pmcid: 8170860
S. Bossoni, L. Chiesa, A. Giustina, Severe hypocalcemia in a thyroidectomized woman with Covid-19 infection. Endocrine 68(2), 253–254 (2020). https://doi.org/10.1007/s12020-020-02326-0
doi: 10.1007/s12020-020-02326-0
pubmed: 32346814
pmcid: 7188455
L. di Filippo, M. Doga, S. Frara, A. Giustina, Hypocalcemia in COVID-19: Prevalence, clinical significance and therapeutic implications. Rev. Endocr. Metab. Disord. 23(2), 299–308 (2022). https://doi.org/10.1007/s11154-021-09655-z
doi: 10.1007/s11154-021-09655-z
pubmed: 33846867
L. Di Filippo, A.M. Formenti, P. Rovere-Querini et al. Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19. Endocrine 68(3), 475–478 (2020). https://doi.org/10.1007/s12020-020-02383-5
doi: 10.1007/s12020-020-02383-5
pubmed: 32533508
pmcid: 7292572
J. Liu, P. Han, J. Wu, J. Gong, D. Tian, Prevalence and predictive value of hypocalcemia in severe COVID-19 patients. J. Infect. Public Health 13(9), 1224–1228 (2020). https://doi.org/10.1016/j.jiph.2020.05.029
doi: 10.1016/j.jiph.2020.05.029
pubmed: 32622796
pmcid: 7306733
J.K. Sun, W.H. Zhang, L. Zou et al. Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease 2019. Aging (Albany NY) 12(12), 11287–11295 (2020). https://doi.org/10.18632/aging.103526
doi: 10.18632/aging.103526
L. di Filippo, A.M. Formenti, M. Doga et al. Hypocalcemia is a distinctive biochemical feature of hospitalized COVID-19 patients. Endocrine 71(1), 9–13 (2021). https://doi.org/10.1007/s12020-020-02541-9
doi: 10.1007/s12020-020-02541-9
pubmed: 33165763
M. Mehta, H. Ghani, F. Chua et al. Retrospective case-control study to evaluate hypocalcaemia as a distinguishing feature of COVID-19 compared with other infective pneumonias and its association with disease severity. BMJ Open. 11(12), e053810 (2021). https://doi.org/10.1136/bmjopen-2021-053810 .
doi: 10.1136/bmjopen-2021-053810
pubmed: 34876435
R. Pal, S. Ram, D. Zohmangaihi et al. High prevalence of hypocalcemia in non-severe COVID-19 patients: a retrospective case-control study. Front. Med. (Lausanne) 7, 590805 (2021). https://doi.org/10.3389/fmed.2020.590805 .
doi: 10.3389/fmed.2020.590805
E. Alemzadeh, E. Alemzadeh, M. Ziaee, A. Abedi, H. Salehiniya, The effect of low serum calcium level on the severity and mortality of Covid patients: a systematic review and meta-analysis. Immun. Inflamm. Dis. 9(4), 1219–1228 (2021). https://doi.org/10.1002/iid3.528
doi: 10.1002/iid3.528
pubmed: 34534417
pmcid: 8589360
J.W. Martha, A. Wibowo, R. Pranata, Hypocalcemia is associated with severe COVID-19: a systematic review and meta-analysis. Diabetes Metab. Syndr. 15(1), 337–342 (2021). https://doi.org/10.1016/j.dsx.2021.01.003
doi: 10.1016/j.dsx.2021.01.003
pubmed: 33493853
pmcid: 7832827
L. di Filippo, A.M. Formenti, A. Giustina, Hypocalcemia: the quest for the cause of a major biochemical feature of COVID-19. Endocrine 70(3), 463–464 (2020). https://doi.org/10.1007/s12020-020-02525-9
doi: 10.1007/s12020-020-02525-9
pubmed: 33094473
pmcid: 7580813
Y. Zhou, T.K. Frey, J.J. Yang, Viral calciomics: interplays between Ca2+ and virus. Cell Calcium 46(1), 1–17 (2009). https://doi.org/10.1016/j.ceca.2009.05.005
doi: 10.1016/j.ceca.2009.05.005
pubmed: 19535138
pmcid: 3449087
S. Berlansky, M. Sallinger, H. Grabmayr et al. Calcium signals during SARS-CoV-2 infection: assessing the potential of emerging therapies. Cells 11(2), 253 (2022). https://doi.org/10.3390/cells11020253 .
doi: 10.3390/cells11020253
pubmed: 35053369
pmcid: 8773957
A. Cavezzi, R. Menicagli, E. Troiani, S. Corrao, COVID-19, cation dysmetabolism, sialic acid, CD147, ACE2, viroporins, hepcidin and ferroptosis: a possible unifying hypothesis. F1000Res. 11, 102 (2022). https://doi.org/10.12688/f1000research.108667.2 .
doi: 10.12688/f1000research.108667.2
pubmed: 35340277
pmcid: 8921693
COVID-19 Autopsy, Electronic address: anapat.hrc@salud.madrid.org. The first COVID-19 autopsy in Spain performed during the early stages of the pandemic. Rev. Esp. Patol. 53(3), 182–187 (2020). https://doi.org/10.1016/j.patol.2020.05.004
doi: 10.1016/j.patol.2020.05.004
J. Kalbhenn, J. Knoerlein, Intramuscular deposit of calcium is a potential reason for hypocalcaemia in COVID-19. Endocrine 72(1), 24–26 (2021). https://doi.org/10.1007/s12020-021-02708-y
doi: 10.1007/s12020-021-02708-y
pubmed: 33830438
pmcid: 8027705
E.P. Brass, W.B. Forman, R.V. Edwards, O. Lindan, Fibrin formation: effect of calcium ions. Blood 52(4), 654–658 (1978). https://doi.org/10.1182/blood.V52.4.654.654
doi: 10.1182/blood.V52.4.654.654
pubmed: 687825
X. Qi, H. Kong, W. Ding et al. Abnormal coagulation function of patients with COVID-19 is significantly related to hypocalcemia and severe inflammation. Front. Med. (Lausanne) 8, 638194 (2021). https://doi.org/10.3389/fmed.2021.638194
doi: 10.3389/fmed.2021.638194
L. Di Filippo, R. De Lorenzo, M. D’Amico et al. COVID-19 is associated with clinically significant weight loss and risk of malnutrition, independent of hospitalisation: a post-hoc analysis of a prospective cohort study. Clin. Nutr. 40(4), 2420–2426 (2021). https://doi.org/10.1016/j.clnu.2020.10.043
doi: 10.1016/j.clnu.2020.10.043
pubmed: 33160700
V.P. Singh, B. Khatua, B. El-Kurdi, C. Rood, Mechanistic basis and therapeutic relevance of hypocalcemia during severe COVID-19 infection. Endocrine 70(3), 461–462 (2020). https://doi.org/10.1007/s12020-020-02530-y
doi: 10.1007/s12020-020-02530-y
pubmed: 33099749
pmcid: 7585352
L. di Filippo, A. Allora, M. Locatelli et al. Hypocalcemia in COVID-19 is associated with low vitamin D levels and impaired compensatory PTH response. Endocrine 74(2), 219–225 (2021). https://doi.org/10.1007/s12020-021-02882-z
doi: 10.1007/s12020-021-02882-z
pubmed: 34586582
pmcid: 8480127
A. Linglart, A.S. Lambert, Approach to patient with severe hypocalcaemia. In Oxford Textbook of Clinical Nephrology, 4th edn, ch. 38, pp 378–383. N. Turner, N. Lameire, D. Goldsmith, C. Winearls, J. Himmelfarb & G. Remuzzi, Eds New York, NY: Oxford University Press, 2015
N.J. Gittoes, S. Criseno, N.M. Appelman-Dijkstra et al. Endocrinology in the time of COVID-19: Management of calcium metabolic disorders and osteoporosis. Eur. J. Endocrinol. 183(2), G57–G65 (2020). https://doi.org/10.1530/EJE-20-0385
doi: 10.1530/EJE-20-0385
pubmed: 32396134
pmcid: 7938011
F. Tecilazich, A.M. Formenti, S. Frara, R. Giubbini, A. Giustina, Treatment of hypoparathyroidism. Best. Pr. Res Clin. Endocrinol. Metab. 32(6), 955–964 (2018). https://doi.org/10.1016/j.beem.2018.12.002
doi: 10.1016/j.beem.2018.12.002
M.A. Gameil, R.E. Marzouk, A.H. Elsebaie, S.E. Rozaik, Long-term clinical and biochemical residue after COVID-19 recovery. Egypt Liver J. 11(1), 74 (2021). https://doi.org/10.1186/s43066-021-00144-1
doi: 10.1186/s43066-021-00144-1
pubmed: 34777873
R. Pal, A. Joshi, S.K. Bhadada, M. Banerjee, S. Vaikkakara, S. Mukhopadhyay, Endocrine follow-up during post-acute COVID-19: Practical recommendations based on available clinical evidence. Endocr. Pr. 28(4), 425–432 (2022). https://doi.org/10.1016/j.eprac.2022.02.003
doi: 10.1016/j.eprac.2022.02.003
A. Giustina, A.M. Formenti (2020) Does hypovitaminosis D play a role in the high impact of COVID infection in Italy? British Medical Journal Available at: https://www.bmj.com/content/368/bmj.m810/rr-36
R. Bouillon, C. Marcocci, G. Carmeliet et al. Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions. Endocr. Rev. 40(4), 1109–1151 (2019). https://doi.org/10.1210/er.2018-00126
doi: 10.1210/er.2018-00126
pubmed: 30321335
J.P. Bilezikian, D. Bikle, M. Hewison et al. Mechanisms in endocrinology: vitamin D and COVID-19. Eur. J. Endocrinol. 183(5), R133–R147 (2020). https://doi.org/10.1530/EJE-20-0665
doi: 10.1530/EJE-20-0665
pubmed: 32755992
pmcid: 9494342
N. Charoenngam, M.F. Holick, Immunologic effects of vitamin D on human health and disease. Nutrients 12(7), 2097 (2020). https://doi.org/10.3390/nu12072097
doi: 10.3390/nu12072097
pmcid: 7400911
H.A. Dissanayake, N.L. de Silva, M. Sumanatilleke et al. Prognostic and therapeutic role of vitamin D in COVID-19: systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 107(5), 1484–1502 (2022). https://doi.org/10.1210/clinem/dgab892
doi: 10.1210/clinem/dgab892
pubmed: 34894254
R. Hopefl, M. Ben-Eltriki, S. Deb, Association between vitamin D levels and inflammatory markers in COVID-19 patients: a meta-analysis of observational studies. J. Pharm. Pharm. Sci. 25, 124–136 (2022). https://doi.org/10.18433/jpps32518
doi: 10.18433/jpps32518
pubmed: 35379386
I. Chiodini, D. Gatti, D. Soranna et al. Vitamin D status and SARS-CoV-2 infection and COVID-19 clinical outcomes. Front Public Health 9, 736665 (2021). https://doi.org/10.3389/fpubh.2021.736665 . Published 2021 Dec 22
doi: 10.3389/fpubh.2021.736665
pubmed: 35004568
pmcid: 8727532
M.R. Akbar, A. Wibowo, R. Pranata, B. Setiabudiawan, Low Serum 25-hydroxyvitamin D (Vitamin D) level is associated with susceptibility to COVID-19, severity, and mortality: a systematic review and meta-analysis [published correction appears in Front Nutr. 2021 Sep 27;8:754539]. Front Nutr. 8, 660420 (2021). https://doi.org/10.3389/fnut.2021.660420
doi: 10.3389/fnut.2021.660420
pubmed: 33855042
pmcid: 8039288
A. Giustina, R.A. Adler, N. Binkley et al. Controversies in vitamin D: summary statement from an international conference. J. Clin. Endocrinol. Metab. 104(2), 234–240 (2019). https://doi.org/10.1210/jc.2018-01414
doi: 10.1210/jc.2018-01414
pubmed: 30383226
A. Giustina, R.A. Adler, N. Binkley et al. Consensus statement from 2nd International Conference on Controversies in Vitamin D. Rev. Endocr. Metab. Disord. 21(1), 89–116 (2020). https://doi.org/10.1007/s11154-019-09532-w
doi: 10.1007/s11154-019-09532-w
pubmed: 32180081
pmcid: 7113202
M.L. Brandi, A. Giustina, Sexual dimorphism of coronavirus 19 morbidity and lethality. Trends Endocrinol. Metab. 31(12), 918–927 (2020). https://doi.org/10.1016/j.tem.2020.09.003
doi: 10.1016/j.tem.2020.09.003
pubmed: 33082024
pmcid: 7513816
E. Maddaloni, I. Cavallari, N. Napoli, C. Conte, Vitamin D and diabetes mellitus. Front Horm. Res. 50, 161–176 (2018). https://doi.org/10.1159/000486083
doi: 10.1159/000486083
pubmed: 29597238
F. Tecilazich, A.M. Formenti, A. Giustina, Role of vitamin D in diabetic retinopathy: pathophysiological and clinical aspects. Rev. Endocr. Metab. Disord. 22(4), 715–727 (2021). https://doi.org/10.1007/s11154-020-09575-4
doi: 10.1007/s11154-020-09575-4
pubmed: 33026598
C. Conte, A. Esposito, R. De Lorenzo et al. Epicardial adipose tissue characteristics, obesity and clinical outcomes in COVID-19: a post-hoc analysis of a prospective cohort study. Nutr. Metab. Cardiovasc Dis. 31(7), 2156–2164 (2021). https://doi.org/10.1016/j.numecd.2021.04.020
doi: 10.1016/j.numecd.2021.04.020
pubmed: 34059384
pmcid: 8091800
L. Di Filippo, R. De Lorenzo, A. Giustina, P. Rovere-Querini, C. Conte, Vitamin D in osteosarcopenic obesity. Nutrients 14(9), 1816 (2022). https://doi.org/10.3390/nu14091816
doi: 10.3390/nu14091816
pubmed: 35565781
pmcid: 9100750
A. Giustina, Hypovitaminosis D and the endocrine phenotype of COVID-19. Endocrine 72(1), 1–11 (2021). https://doi.org/10.1007/s12020-021-02671-8
doi: 10.1007/s12020-021-02671-8
pubmed: 33738708
pmcid: 7972333
N. Hutchings, V. Babalyan, S. Baghdasaryan et al. Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D. Endocrine 71(2), 267–269 (2021). https://doi.org/10.1007/s12020-020-02597-7
doi: 10.1007/s12020-020-02597-7
pubmed: 33452994
pmcid: 7811339
L. di Filippo, A. Allora, M. Doga et al. Vitamin D levels are associated with blood glucose and BMI in COVID-19 patients, predicting disease severity. J. Clin. Endocrinol. Metab. 107(1), e348–e360 (2022). https://doi.org/10.1210/clinem/dgab599
doi: 10.1210/clinem/dgab599
pubmed: 34383926
F.M. Ulivieri, G. Banfi, V. Camozzi et al. Vitamin D in the Covid-19 era: a review with recommendations from a G.I.O.S.E.G. expert panel. Endocrine 72(3), 597–603 (2021). https://doi.org/10.1007/s12020-021-02749-3
doi: 10.1007/s12020-021-02749-3
pubmed: 33999367
pmcid: 8127472
J.P. Bilezikian, A.M. Formenti, R.A. Adler et al. Vitamin D: dosing, levels, form, and route of administration: does one approach fit all? Rev. Endocr. Metab. Disord. 22(4), 1201–1218 (2021). https://doi.org/10.1007/s11154-021-09693-7
doi: 10.1007/s11154-021-09693-7
pubmed: 34940947
pmcid: 8696970
K. Shah, V.P. Varna, U. Sharma, D. Mavalankar, Does vitamin D supplementation reduce COVID-19 severity? - a systematic review [published online ahead of print, 2022 Feb 15]. QJM. 2022;hcac040. https://doi.org/10.1093/qjmed/hcac040
S.R. Varikasuvu, B. Thangappazham, A. Vykunta, et al. COVID-19 and vitamin D (Co-VIVID study): a systematic review and meta-analysis of randomized controlled trials [published online ahead of print, 2022 Feb 3]. Expert Rev Anti Infect Ther. 2022;1–7. https://doi.org/10.1080/14787210.2022.2035217
N. Tentolouris, G. Samakidou, I. Eleftheriadou, A. Tentolouris, E.B. Jude, The effect of vitamin D supplementation on mortality and intensive care unit admission of COVID-19 patients. A systematic review, meta-analysis and meta-regression. Diabetes Metab. Res Rev. 38(4), e3517 (2022). https://doi.org/10.1002/dmrr.3517
doi: 10.1002/dmrr.3517
pubmed: 34965318
pmcid: 9015406
R. Pal, M. Banerjee, S.K. Bhadada, A.J. Shetty, B. Singh, A. Vyas, Vitamin D supplementation and clinical outcomes in COVID-19: a systematic review and meta-analysis. J. Endocrinol. Invest 45(1), 53–68 (2022). https://doi.org/10.1007/s40618-021-01614-4
doi: 10.1007/s40618-021-01614-4
pubmed: 34165766
A. Nalbandian, K. Sehgal, A. Gupta et al. Post-acute COVID-19 syndrome. Nat. Med 27(4), 601–615 (2021). https://doi.org/10.1038/s41591-021-01283-z
doi: 10.1038/s41591-021-01283-z
pubmed: 33753937
pmcid: 8893149
L. Di Filippo, R. De Lorenzo, E. Cinel et al. Weight trajectories and abdominal adiposity in COVID-19 survivors with overweight/obesity. Int J. Obes. (Lond.) 45(9), 1986–1994 (2021). https://doi.org/10.1038/s41366-021-00861-y
doi: 10.1038/s41366-021-00861-y
L.E. Heaton, J.K. Davis, E.S. Rawson et al. Selected in-season nutritional strategies to enhance recovery for team sport athletes: a practical overview. Sports Med. 47(11), 2201–2218 (2017). https://doi.org/10.1007/s40279-017-0759-2
doi: 10.1007/s40279-017-0759-2
pubmed: 28702900
pmcid: 5633631
T. Barker, E.D. Schneider, B.M. Dixon, V.T. Henriksen, L.K. Weaver, Supplemental vitamin D enhances the recovery in peak isometric force shortly after intense exercise. Nutr. Metab. (Lond) 10(1), 69 (2013). https://doi.org/10.1186/1743-7075-10-69
doi: 10.1186/1743-7075-10-69
G. El-Hajj Fuleihan, M. Nabulsi, H. Tamim et al. Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial. J. Clin. Endocrinol. Metab. 91(2), 405–412 (2006). https://doi.org/10.1210/jc.2005-1436
doi: 10.1210/jc.2005-1436
pubmed: 16278262
J. Haugen, S. Basnet, I.M. Hardang et al. Vitamin D status is associated with treatment failure and duration of illness in Nepalese children with severe pneumonia. Pediatr. Res. 82(6), 986–993 (2017). https://doi.org/10.1038/pr.2017.71
doi: 10.1038/pr.2017.71
pubmed: 28678771
A. Caballero-García, D. Pérez-Valdecantos, P. Guallar et al. Effect of vitamin D supplementation on muscle status in old patients recovering from COVID-19 infection. Med. (Kaunas) 57(10), 1079 (2021). https://doi.org/10.3390/medicina57101079
doi: 10.3390/medicina57101079
L. Townsend, A.H. Dyer, P. McCluskey et al. Investigating the relationship between vitamin D and persistent symptoms following SARS-CoV-2 infection. Nutrients 13(7), 2430 (2021). https://doi.org/10.3390/nu13072430
doi: 10.3390/nu13072430
pubmed: 34371940
pmcid: 8308626
A.A.R. Mohamed Hussein, I. Galal, M.T. Amin et al. Prevalence of vitamin D deficiency among patients attending Post COVID-19 follow-up clinic: a cross-sectional study. Eur. Rev. Med Pharm. Sci. 26(8), 3038–3045 (2022). https://doi.org/10.26355/eurrev_202204_28635
doi: 10.26355/eurrev_202204_28635
L. Barrea, W.B. Grant, E. Frias-Toral et al. Dietary recommendations for post-COVID-19 syndrome. Nutrients 14(6), 1305 (2022). https://doi.org/10.3390/nu14061305
doi: 10.3390/nu14061305
pubmed: 35334962
pmcid: 8954128
L. di Filippo, L. Castellino, A. Giustina, Occurrence and response to treatment of Graves’ disease after COVID vaccination in two male patients. Endocrine 75(1), 19–21 (2022). https://doi.org/10.1007/s12020-021-02919-3
doi: 10.1007/s12020-021-02919-3
pubmed: 34727295
I. Piec, L. Cook, S. Dervisevic et al. Age and vitamin D affect the magnitude of the antibody response to the first dose of the SARS-CoV-2 BNT162b2 vaccine [published online ahead of print, 2022 Mar 16]. Curr. Res. Transl. Med. 70(3), 103344 (2022). https://doi.org/10.1016/j.retram.2022.103344
doi: 10.1016/j.retram.2022.103344
pubmed: 35390564
pmcid: 8923881
T.S. Chillon, K. Demircan, R.A. Heller et al. Relationship between vitamin D status and antibody response to COVID-19 mRNA vaccination in healthy adults. Biomedicines 9(11), 1714 (2021). https://doi.org/10.3390/biomedicines9111714
doi: 10.3390/biomedicines9111714
pubmed: 34829945
pmcid: 8615783
M.D. Lee, C.H. Lin, W.T. Lei et al. Does vitamin D deficiency affect the immunogenic responses to influenza vaccination? a systematic review and meta-analysis. Nutrients 10(4), 409 (2018). https://doi.org/10.3390/nu10040409
doi: 10.3390/nu10040409
pmcid: 5946194
M.K. Lalor, S. Floyd, P. Gorak-Stolinska et al. BCG vaccination: a role for vitamin D? PLoS One 6(1), e16709 (2011). https://doi.org/10.1371/journal.pone.0016709
doi: 10.1371/journal.pone.0016709
pubmed: 21304967
pmcid: 3031626
E. Zitt, H. Sprenger-Mähr, F. Knoll, U. Neyer, K. Lhotta, Vitamin D deficiency is associated with poor response to active hepatitis B immunisation in patients with chronic kidney disease. Vaccine 30(5), 931–935 (2012). https://doi.org/10.1016/j.vaccine.2011.11.086
doi: 10.1016/j.vaccine.2011.11.086
pubmed: 22142584
A. Giustina, R. Bouillon, N. Binkley et al. Controversies in vitamin D: a statement from the Third International Conference. JBMR 4(12), e10417 (2020). https://doi.org/10.1002/jbm4.10417
doi: 10.1002/jbm4.10417
J.B. Bonnet, E. Berchoux, A. Sultan, Decompensated primary hypoparathyroidism in a patient with COVID-19. Ann. Endocrinol. 82(2), 123–124 (2021). https://doi.org/10.1016/j.ando.2021.02.002
doi: 10.1016/j.ando.2021.02.002
J.L. Hernández, D. Nan, M. Fernandez-Ayala et al. Vitamin D status in hospitalized patients with SARS-CoV-2 infection. J. Clin. Endocrinol. Metab. 106(3), e1343–e1353 (2021). https://doi.org/10.1210/clinem/dgaa733
doi: 10.1210/clinem/dgaa733
pubmed: 34932810
G. Mazziotti, E. Lavezzi, A. Brunetti et al. Vitamin D deficiency, secondary hyperparathyroidism and respiratory insufficiency in hospitalized patients with COVID-19. J. Endocrinol. Invest. 44(10), 2285–2293 (2021). https://doi.org/10.1007/s40618-021-01535-2
doi: 10.1007/s40618-021-01535-2
pubmed: 33666876
pmcid: 7934807
A. Kelly, M.A. Levine, Hypocalcemia in the critically ill patient. J. Intensive Care Med. 28(3), 166–177 (2013). https://doi.org/10.1177/0885066611411543
doi: 10.1177/0885066611411543
pubmed: 21841146
R. Krapf, P. Jaeger, H.N. Hulter, Chronic respiratory alkalosis induces renal PTH-resistance, hyperphosphatemia and hypocalcemia in humans. Kidney Int. 42(3), 727–734 (1992). https://doi.org/10.1038/ki.1992.340
doi: 10.1038/ki.1992.340
pubmed: 1405350
Y. Ding, L. He, Q. Zhang et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J. Pathol. 203(2), 622–630 (2004). https://doi.org/10.1002/path.1560
doi: 10.1002/path.1560
pubmed: 15141376
pmcid: 7167761
L. He, Y. Ding, Q. Zhang et al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J. Pathol. 210(3), 288–297 (2006). https://doi.org/10.1002/path.2067
doi: 10.1002/path.2067
pubmed: 17031779
pmcid: 7167655
S. Elkattawy, R. Alyacoub, S. Ayad, M. Pandya, A. Eckman, A novel case of hypoparathyroidism secondary to SARS-CoV-2 infection. Cureus 12(8), e10097 (2020). https://doi.org/10.7759/cureus.10097
doi: 10.7759/cureus.10097
pubmed: 33005518
pmcid: 7522187
M. Dianatfar, M. Sanjari, B. Dalfardi, Hypoparathyroidism After COVID-19 pneumonia. Magnesium 33(30-100), 7 (2021)
V.E. Georgakopoulou, P. Avramopoulos, P. Papalexis et al. COVID-19 induced hypoparathyroidism: a case report. Exp. Ther. Med. 23(5), 346 (2022). https://doi.org/10.3892/etm.2022.11276
doi: 10.3892/etm.2022.11276
pubmed: 35401797
pmcid: 8988155
V. Trapani, A. Rosanoff, S. Baniasadi et al. The relevance of magnesium homeostasis in COVID-19. Eur. J. Nutr. 61(2), 625–636 (2022). https://doi.org/10.1007/s00394-021-02704-y
doi: 10.1007/s00394-021-02704-y
pubmed: 34687321
R. Sharma, A. Heidari, R.H. Johnson, S. Advani, G. Petersen, Serum magnesium levels in hospitalized patients with SARS-CoV-2. J. Investig. Med. 70(2), 409–414 (2022). https://doi.org/10.1136/jim-2021-001948
doi: 10.1136/jim-2021-001948
pubmed: 34580159
T. Vetter, M.J. Lohse, Magnesium and the parathyroid. Curr. Opin. Nephrol. Hypertens. 11(4), 403–410 (2002). https://doi.org/10.1097/00041552-200207000-00006
doi: 10.1097/00041552-200207000-00006
pubmed: 12105390
L. di Filippo, A.M. Formenti, M. Doga, E. Pedone, P. Rovere-Querini, A. Giustina, Radiological thoracic vertebral fractures are highly prevalent in COVID-19 and predict disease outcomes. J. Clin. Endocrinol. Metab. 106(2), e602–e614 (2021). https://doi.org/10.1210/clinem/dgaa738
doi: 10.1210/clinem/dgaa738
pubmed: 33159451
T. Jalava, S. Sarna, L. Pylkkänen et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J. Bone Min. Res. 18(7), 1254–1260 (2003). https://doi.org/10.1359/jbmr.2003.18.7.1254
doi: 10.1359/jbmr.2003.18.7.1254
S. Battisti, N. Napoli, C. Pedone et al. Vertebral fractures and mortality risk in hospitalised patients during the COVID-19 pandemic emergency. Endocrine 74(3), 461–469 (2021). https://doi.org/10.1007/s12020-021-02872-1
doi: 10.1007/s12020-021-02872-1
pubmed: 34529239
pmcid: 8444515
J. Kottlors, N. Große Hokamp, P. Fervers et al. Early extrapulmonary prognostic features in chest computed tomography in COVID-19 pneumonia: Bone mineral density is a relevant predictor for the clinical outcome - a multicenter feasibility study. Bone 144, 115790 (2021). https://doi.org/10.1016/j.bone.2020.115790
doi: 10.1016/j.bone.2020.115790
pubmed: 33301962
M. Tahtabasi, N. Kilicaslan, Y. Akin et al. The prognostic value of vertebral bone density on chest CT in hospitalized COVID-19 patients. J. Clin. Densitom. 24(4), 506–515 (2021). https://doi.org/10.1016/j.jocd.2021.07.007
doi: 10.1016/j.jocd.2021.07.007
pubmed: 34353732
pmcid: 8302819
N. Napoli, A.L. Elderkin, D.P. Kiel, S. Khosla, Managing fragility fractures during the COVID-19 pandemic. Nat. Rev. Endocrinol. 16(9), 467–468 (2020). https://doi.org/10.1038/s41574-020-0379-z
doi: 10.1038/s41574-020-0379-z
pubmed: 32528045
pmcid: 7288256
G.R. Emkey, S. Epstein, Secondary osteoporosis: pathophysiology & diagnosis. Best. Pr. Res Clin. Endocrinol. Metab. 28(6), 911–935 (2014). https://doi.org/10.1016/j.beem.2014.07.002
doi: 10.1016/j.beem.2014.07.002
G. Mazziotti, M. Baracca, M. Doga, T. Porcelli, P.P. Vescovi, A. Giustina, Prevalence of thoracic vertebral fractures in hospitalized elderly patients with heart failure. Eur. J. Endocrinol. 167(6), 865–872 (2012). https://doi.org/10.1530/EJE-12-0566
doi: 10.1530/EJE-12-0566
pubmed: 22968484
S. Boussaid, Y. Makhlouf, S. Jammali, H. Sahli, M. Elleuch, S. Rekik, Association of SARS-COV2 and lumbar spine fractures: causal or coincidental? [published online ahead of print, 2021 Nov 26]. J Clin Densitom. 2021;S1094–6950(21)00095-0. https://doi.org/10.1016/j.jocd.2021.11.006
G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41(1), 58–69 (2012). https://doi.org/10.1007/s12020-011-9570-2
doi: 10.1007/s12020-011-9570-2
pubmed: 22180055
B. Kim, J. Kim, Y.H. Jo et al. Risk of pneumonia after vertebral compression fracture in women with low bone density: a population-based study. Spine (Philos. Pa 1976) 43(14), E830–E835 (2018). https://doi.org/10.1097/BRS.0000000000002536
doi: 10.1097/BRS.0000000000002536
R. Watanabe, M. Shiraki, M. Saito, R. Okazaki, D. Inoue, Restrictive pulmonary dysfunction is associated with vertebral fractures and bone loss in elderly postmenopausal women. Osteoporos. Int. 29(3), 625–633 (2018). https://doi.org/10.1007/s00198-017-4337-0
doi: 10.1007/s00198-017-4337-0
pubmed: 29218382
J.H. Krege, D. Kendler, K. Krohn et al. Relationship between vertebral fracture burden, height loss, and pulmonary function in postmenopausal women with osteoporosis. J. Clin. Densitom. 18(4), 506–511 (2015). https://doi.org/10.1016/j.jocd.2015.02.004
doi: 10.1016/j.jocd.2015.02.004
pubmed: 25824332
L. di Filippo, N. Compagnone, S. Frara, et al. Vertebral fractures at hospitalization predict impaired respiratory function during follow-up of COVID-19 survivors [published online ahead of print, 2022 Jun 8]. Endocrine. 2022. https://doi.org/10.1007/s12020-022-03096-7
A.M. Formenti, E. Pedone, L. di Filippo, F.M. Ulivieri, A. Giustina, Are women with osteoporosis treated with denosumab at risk of severe COVID-19. Endocrine 70(2), 203–205 (2020). https://doi.org/10.1007/s12020-020-02500-4
doi: 10.1007/s12020-020-02500-4
pubmed: 32951069
pmcid: 7502215
J. Blanch-Rubió, N. Soldevila-Domenech, L. Tío et al. Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions. Aging (Albany NY) 12(20), 19923–19937 (2020). https://doi.org/10.18632/aging.104117
doi: 10.18632/aging.104117
A. Atmaca, I. Demirci, C. Haymana et al. No association of anti-osteoporosis drugs with COVID-19-related outcomes in women: a nationwide cohort study. Osteoporos. Int. 33(1), 273–282 (2022). https://doi.org/10.1007/s00198-021-06067-2
doi: 10.1007/s00198-021-06067-2
pubmed: 34402949
E. Tsourdi, E.W. Yu, S.M. Jan de Beur, M.T. Drake, Vaccination for Coronavirus Disease 2019 (COVID-19) and relationship to osteoporosis care: current evidence and suggested approaches. J. Bone Min. Res. 36(6), 1042–1047 (2021). https://doi.org/10.1002/jbmr.4304
doi: 10.1002/jbmr.4304
A. Giustina, M. Marazuela, M. Reincke, B.O. Yildiz, M. Puig-Domingo, One year of the pandemic - how European endocrinologists responded to the crisis: a statement from the European Society of Endocrinology. Eur. J. Endocrinol. 185(2), C1–C7 (2021). https://doi.org/10.1530/EJE-21-0397
doi: 10.1530/EJE-21-0397
pubmed: 34132200
pmcid: 9494341